[{"id":"1ee7d622-cdd0-4c14-a5ad-ff67b7a251a6","acronym":"NCI-2021-11793","url":"https://clinicaltrials.gov/study/NCT05111561","created_at":"2021-11-08T14:53:11.471Z","updated_at":"2025-02-25T13:40:41.596Z","phase":"Phase 1","brief_title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05111561 - NCI-2021-11793","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion","tags":["HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib) • ZEN-3694"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 08/02/2022","start_date":" 08/02/2022","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-21"},{"id":"f7e6df94-a121-41c2-ab20-30322990863a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05327010","created_at":"2022-04-14T12:53:52.597Z","updated_at":"2025-02-25T14:02:49.505Z","phase":"Phase 2","brief_title":"Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial","source_id_and_acronym":"NCT05327010","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation","tags":["KRAS • BRCA1 • BRCA2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD51D • BARD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12 • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 88","initiation":"Initiation: 11/14/2022","start_date":" 11/14/2022","primary_txt":" Primary completion: 08/04/2025","primary_completion_date":" 08/04/2025","study_txt":" Completion: 08/04/2025","study_completion_date":" 08/04/2025","last_update_posted":"2025-02-19"},{"id":"0e6f9786-f03c-47e3-82a4-50892d86b673","acronym":"","url":"https://clinicaltrials.gov/study/NCT06102902","created_at":"2023-10-26T15:14:21.567Z","updated_at":"2025-02-25T14:10:15.325Z","phase":"Phase 1","brief_title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","source_id_and_acronym":"NCT06102902","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Braftovi (encorafenib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/05/2024","start_date":" 06/05/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-17"},{"id":"d94f7980-52bd-4422-b97d-6ffc7470ef49","acronym":"NRG-GY031","url":"https://clinicaltrials.gov/study/NCT05950464","created_at":"2023-07-20T15:09:28.523Z","updated_at":"2025-02-25T14:42:14.385Z","phase":"Phase 1","brief_title":"Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT05950464 - NRG-GY031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694 • tuvusertib (M1774)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-14"},{"id":"64d1ef99-04c4-4d5a-830b-60a55b2be129","acronym":"","url":"https://clinicaltrials.gov/study/NCT05422794","created_at":"2022-06-22T01:54:45.793Z","updated_at":"2025-02-25T16:39:06.146Z","phase":"Phase 1","brief_title":"Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05422794","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • albumin-bound paclitaxel • ZEN-3694 • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 05/18/2023","start_date":" 05/18/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"5b3bbfcb-81b9-4094-b5ab-f48bff41c08a","acronym":"NCI-2022-04099","url":"https://clinicaltrials.gov/study/NCT05372640","created_at":"2022-05-13T12:54:24.439Z","updated_at":"2025-02-25T16:46:03.280Z","phase":"Phase 1","brief_title":"Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors","source_id_and_acronym":"NCT05372640 - NCI-2022-04099","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NUTM1","pipe":"","alterations":" ","tags":["NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-05"},{"id":"1056dca4-95a8-462c-8bb1-1287b2e57c22","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161493","created_at":"2023-12-08T17:16:39.097Z","updated_at":"2025-02-25T13:13:32.183Z","phase":"Phase 1","brief_title":"ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors","source_id_and_acronym":"NCT06161493","lead_sponsor":"Haider Mahdi","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • ZEN-3694"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/23/2024","start_date":" 01/23/2024","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2024-10-11"},{"id":"70736adb-b060-44c5-baf0-08a2f859c924","acronym":"","url":"https://clinicaltrials.gov/study/NCT04471974","created_at":"2021-01-18T21:29:11.594Z","updated_at":"2025-02-25T16:10:30.954Z","phase":"Phase 2","brief_title":"ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04471974","lead_sponsor":"Rahul Aggarwal","biomarkers":" PD-L1 • RB1","pipe":" | ","alterations":" RB1 deletion • RB deletion","tags":["PD-L1 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 deletion • RB deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xtandi (enzalutamide) • ZEN-3694 • ZEN-3219"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2024-04-26"},{"id":"b6dca039-ae2d-4e16-87dc-6e74f95f97fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT02516553","created_at":"2021-01-18T12:09:36.817Z","updated_at":"2024-07-02T16:35:09.784Z","phase":"Phase 1","brief_title":"BI 894999 First in Human Dose Finding Study in Advanced Malignancies","source_id_and_acronym":"NCT02516553","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e amredobresib (BI 894999)"],"overall_status":"Completed","enrollment":" Enrollment 174","initiation":"Initiation: 07/08/2015","start_date":" 07/08/2015","primary_txt":" Primary completion: 11/23/2021","primary_completion_date":" 11/23/2021","study_txt":" Completion: 11/23/2021","study_completion_date":" 11/23/2021","last_update_posted":"2024-04-15"},{"id":"938d3f31-19a2-4d93-b968-94fc075d0fd5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03936465","created_at":"2021-01-18T19:23:12.104Z","updated_at":"2024-07-02T16:35:13.440Z","phase":"Phase 1","brief_title":"Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer","source_id_and_acronym":"NCT03936465","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • MYCN • BRD4 • BRD3","pipe":" | ","alterations":" MYCN amplification","tags":["MYC • MYCN • BRD4 • BRD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezobresib (BMS-986158) • trotabresib (BMS-986378)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/27/2019","start_date":" 09/27/2019","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 07/16/2024","study_completion_date":" 07/16/2024","last_update_posted":"2024-03-21"},{"id":"522c49af-78dd-4744-a59b-263e97c777c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05019716","created_at":"2021-08-25T14:53:05.366Z","updated_at":"2024-07-02T16:35:16.121Z","phase":"Phase 1/2","brief_title":"Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","source_id_and_acronym":"NCT05019716","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRD4 • NUTM1","pipe":"","alterations":" ","tags":["BRD4 • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-03-06"},{"id":"5b5ad733-eb31-4840-89b9-4c48183883d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05607108","created_at":"2022-11-07T13:56:22.739Z","updated_at":"2024-07-02T16:35:24.823Z","phase":"Phase 2","brief_title":"A Study of ZEN003694 in People With Squamous Cell Lung Cancer","source_id_and_acronym":"NCT05607108","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" NSD3","pipe":"","alterations":" ","tags":["NSD3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-01"},{"id":"00cc548c-4f04-43c7-b861-7b41b6484b2c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05071937","created_at":"2021-10-08T11:53:52.361Z","updated_at":"2024-07-02T16:35:27.795Z","phase":"Phase 2","brief_title":"ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05071937","lead_sponsor":"Haider Mahdi","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • ZEN-3694"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 04/13/2023","start_date":" 04/13/2023","primary_txt":" Primary completion: 12/01/2029","primary_completion_date":" 12/01/2029","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2023-11-29"},{"id":"8394813c-9f2d-4565-9201-f9b99aa9b390","acronym":"","url":"https://clinicaltrials.gov/study/NCT02543879","created_at":"2021-01-18T12:18:27.959Z","updated_at":"2024-07-02T16:35:28.491Z","phase":"Phase 1","brief_title":"Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT02543879","lead_sponsor":"Forma Therapeutics, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • CC-95775"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2023-11-21"},{"id":"7005edb3-c23d-4298-af06-34b3265829d6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04324840","created_at":"2021-01-18T20:57:05.594Z","updated_at":"2024-07-02T16:35:29.560Z","phase":"Phase 1","brief_title":"A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT04324840","lead_sponsor":"Celgene","biomarkers":" MGMT","pipe":" | ","alterations":" RAS wild-type • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • trotabresib (BMS-986378)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 194","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 05/12/2024","primary_completion_date":" 05/12/2024","study_txt":" Completion: 05/15/2026","study_completion_date":" 05/15/2026","last_update_posted":"2023-11-10"},{"id":"b00cf327-6db5-41ff-a939-16acf28517b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04089527","created_at":"2021-01-18T20:00:55.948Z","updated_at":"2024-07-02T16:36:17.721Z","phase":"Phase 1b","brief_title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04089527","lead_sponsor":"Celgene","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CC-95775"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 10/24/2019","start_date":" 10/24/2019","primary_txt":" Primary completion: 10/25/2021","primary_completion_date":" 10/25/2021","study_txt":" Completion: 10/25/2021","study_completion_date":" 10/25/2021","last_update_posted":"2022-02-01"},{"id":"5cba854c-bab1-4337-adda-850514168965","acronym":"","url":"https://clinicaltrials.gov/study/NCT03255096","created_at":"2021-01-18T16:04:46.735Z","updated_at":"2024-07-02T16:36:18.132Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6","source_id_and_acronym":"NCT03255096","lead_sponsor":"Hoffmann-La Roche","biomarkers":" MYC • BCL2","pipe":" | ","alterations":" BCL2 expression • MYC expression","tags":["MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • RG6146"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 08/28/2017","start_date":" 08/28/2017","primary_txt":" Primary completion: 07/03/2019","primary_completion_date":" 07/03/2019","study_txt":" Completion: 07/03/2019","study_completion_date":" 07/03/2019","last_update_posted":"2022-01-24"},{"id":"2cd939b3-0ad5-4da7-9783-177794412b1a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01943851","created_at":"2021-01-18T08:48:17.616Z","updated_at":"2024-07-02T16:36:30.033Z","phase":"Phase 2","brief_title":"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies","source_id_and_acronym":"NCT01943851","lead_sponsor":"GlaxoSmithKline","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC overexpression • CD20 expression","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC overexpression • CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e molibresib (GSK525762)"],"overall_status":"Completed","enrollment":" Enrollment 111","initiation":"Initiation: 05/14/2014","start_date":" 05/14/2014","primary_txt":" Primary completion: 04/30/2020","primary_completion_date":" 04/30/2020","study_txt":" Completion: 04/30/2020","study_completion_date":" 04/30/2020","last_update_posted":"2021-05-19"},{"id":"8f7947e2-9124-4105-8e09-87320d4b0bca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03205176","created_at":"2021-01-18T15:48:59.636Z","updated_at":"2024-07-02T16:36:30.672Z","phase":"Phase 1","brief_title":"AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas","source_id_and_acronym":"NCT03205176","lead_sponsor":"AstraZeneca","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • SRA515"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 06/30/2017","start_date":" 06/30/2017","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 04/08/2021","study_completion_date":" 04/08/2021","last_update_posted":"2021-05-06"},{"id":"6b981973-5044-48d8-8609-e2a64de918ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT02392611","created_at":"2021-01-18T11:24:33.676Z","updated_at":"2024-07-02T16:36:36.790Z","phase":"Phase 1","brief_title":"Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer","source_id_and_acronym":"NCT02392611","lead_sponsor":"Gilead Sciences","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • exemestane • alobresib (GS-5829)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/16/2015","start_date":" 03/16/2015","primary_txt":" Primary completion: 10/11/2017","primary_completion_date":" 10/11/2017","study_txt":" Completion: 10/11/2017","study_completion_date":" 10/11/2017","last_update_posted":"2020-12-29"},{"id":"605feb5a-a612-4396-ba99-5fad946a9ff5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04116359","created_at":"2021-01-18T20:07:15.394Z","updated_at":"2024-07-02T16:36:40.639Z","phase":"Phase 1/2","brief_title":"Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma","source_id_and_acronym":"NCT04116359","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRD4 • NUTM1","pipe":"","alterations":" ","tags":["BRD4 • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • etoposide IV • molibresib (GSK525762)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/18/2020","start_date":" 09/18/2020","primary_txt":" Primary completion: 09/18/2020","primary_completion_date":" 09/18/2020","study_txt":" Completion: 09/18/2020","study_completion_date":" 09/18/2020","last_update_posted":"2020-09-28"},{"id":"2cc422f9-bbf0-49cc-8e87-efe44078158e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03702036","created_at":"2021-04-16T05:53:06.992Z","updated_at":"2024-07-02T16:36:46.062Z","phase":"","brief_title":"Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma","source_id_and_acronym":"NCT03702036","lead_sponsor":"GlaxoSmithKline","biomarkers":" NUTM1","pipe":"","alterations":" ","tags":["NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e molibresib (GSK525762)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-04-13"},{"id":"ed89a3b8-b73e-4ee4-aac0-61619bfbd29f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01587703","created_at":"2021-01-18T06:46:16.022Z","updated_at":"2024-07-02T16:36:48.650Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers","source_id_and_acronym":"NCT01587703","lead_sponsor":"GlaxoSmithKline","biomarkers":" ER • MYCN • NUTM1","pipe":" | ","alterations":" ER positive • MYCN amplification","tags":["ER • MYCN • NUTM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e molibresib (GSK525762)"],"overall_status":"Completed","enrollment":" Enrollment 196","initiation":"Initiation: 03/28/2012","start_date":" 03/28/2012","primary_txt":" Primary completion: 04/13/2018","primary_completion_date":" 04/13/2018","study_txt":" Completion: 07/29/2019","study_completion_date":" 07/29/2019","last_update_posted":"2020-03-16"},{"id":"a3d4b8ea-48dd-4cdc-ae07-718e68da89e4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02986919","created_at":"2021-01-18T14:41:37.538Z","updated_at":"2024-07-02T16:37:07.019Z","phase":"Phase 2","brief_title":"Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors","source_id_and_acronym":"NCT02986919","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" BCL2L11","pipe":"","alterations":" ","tags":["BCL2L11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pelabresib (DAK539)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/05/2017","start_date":" 05/05/2017","primary_txt":" Primary completion: 05/17/2018","primary_completion_date":" 05/17/2018","study_txt":" Completion: 05/17/2018","study_completion_date":" 05/17/2018","last_update_posted":"2018-09-11"}]